c-myc oncogene expression: a marker for females at risk of breast carcinoma.
In an attempt to identify patients at risk of breast cancer, 9E 10 c-myc monoclonal antibody was used to detect the oncogene products in 64 breast tissue biopsies. There were 44 specimens of benign breast disorders: 21 from patients who developed subsequent breast cancer, and 23 from patients who did not. The remainder were malignant tumor biopsies from those who developed breast cancer. C-myc over-expression was identified in 12 (60%) of the breast carcinomas; it was also noted in 13 (62%) of the benign biopsies from patients who developed subsequent breast carcinoma. Expression was observed in only 3 (13%) controls--patients who did not develop cancer. A prospective study is now warranted to determine the clinical usefulness of our findings.
Hehir
D J
DJ
Department of Surgery, Cork Regional Hospital, Ireland.
McGreal
G
G
Kirwan
W O
WO
Kealy
W
W
Brady
M P
MP
D000911:Antibodies, Monoclonal; D001941:Breast Diseases / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics*; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D016259:Genes, myc; D005819:Genetic Markers; D006801:Humans; D007150:Immunohistochemistry; D011237:Predictive Value of Tests; D012189:Retrospective Studies
D000911:Antibodies, Monoclonal; D005819:Genetic Markers